Drugs for Gastrointestinal Diseases Practice Questions

Q: Proton pump inhibitors for peptic ulcer disease should be taken:

Before Breakfast. ***Before Breakfast*** - Proton pump inhibitors (PPIs) are most effective when taken **30-60 minutes before the first meal of the day**. - This timing allows the drug to reach peak plasma concentration when the greatest number of **proton pumps** are activated by food intake, maximizing their inhibitory effect on acid secretion. *After Breakfast* - Taking PPIs after breakfast significantly reduces their effectiveness because many **proton pumps** would have already been active and subsequently inactivated before the drug can exert its full effect. - This timing leads to suboptimal acid suppression, potentially hindering the healing of **peptic ulcers**. *Before Dinner* - While taking a second daily dose before dinner can be beneficial for some patients with persistent symptoms, it is not the primary or most effective administration time for a **once-daily dose**. - The main goal is to suppress the **meal-stimulated acid secretion** throughout the day, which is best achieved by the morning dose. *After Dinner* - Administering PPIs after dinner is generally ineffective for the same reasons as taking them after breakfast; the **proton pumps** have already been activated and then inactivated, diminishing the drug's impact. - This timing would lead to inadequate acid control, especially during the day when most acid secretion occurs.

Q: Proton pump inhibitors are most effective when they are given:

Shortly before meals. ***Shortly before meals*** - **Proton pump inhibitors (PPIs)** are most effective when administered 30-60 minutes before a meal because they need to be present when **parietal cells are actively secreting acid**. - PPIs are **prodrugs** that become activated in the acidic environment of the parietal cell secretory canaliculus and then irreversibly bind to the **H+/K+ ATPase pump**. - Taking them before a meal ensures that the drug is absorbed and reaches the parietal cells just as they are being stimulated to secrete acid in response to food, maximizing the number of pumps that can be inhibited. *After meals* - Taking PPIs after meals is less effective because a significant portion of the drug may have already been absorbed during a period of lower parietal cell activity. - This timing misses the optimal window when the maximum number of **proton pumps** are being inserted into the canalicular membrane in response to the meal stimulus. - Additionally, food can interfere with the absorption of some PPIs, further reducing effectiveness. *Along with H2 blockers* - While both PPIs and **H2 blockers** reduce gastric acid through different mechanisms, combining them does not provide significant additional benefit for most conditions. - H2 blockers reduce the basal stimulation of parietal cells, which means fewer pumps are actively secreting when the PPI is present, potentially reducing the number of pumps available for PPI binding. - Routine combination therapy is generally not recommended except in specific refractory cases. *During prolonged fasting periods* - During **fasting**, parietal cells are relatively inactive with minimal pump activity in the secretory canaliculus. - PPIs are most effective when they can bind to actively functioning **H+/K+ ATPase pumps**, which are minimal during fasting states. - This results in fewer pumps being irreversibly inhibited, leading to suboptimal acid suppression.

Q: Which one of the following is a 5-HT3 antagonist?

Ondansetron. ***Ondansetron*** - **Ondansetron** is a highly effective **5-HT3 receptor antagonist** primarily used as an antiemetic, particularly for chemotherapy-induced nausea and vomiting. - It works by blocking serotonin's action on 5-HT3 receptors in the **chemoreceptor trigger zone** and the **gastrointestinal tract**, thereby preventing the emetic reflex. *Orlistat* - **Orlistat** is a medication used for **weight loss** that acts as a **gastrointestinal lipase inhibitor**. - It prevents the absorption of dietary fats by inhibiting enzymes in the gut, rather than affecting serotonin receptors. *Clozapine* - **Clozapine** is an **atypical antipsychotic** medication used primarily in the treatment of **schizophrenia** that is unresponsive to other drugs. - While it has a complex pharmacology involving multiple receptors, its primary mechanism does not involve blocking 5-HT3 receptors. *Ergotamine* - **Ergotamine** is an **ergot alkaloid** primarily used for the treatment of **migraines**. - Its mechanism of action involves partial agonist and antagonist effects on various serotonin, dopamine, and alpha-adrenergic receptors, but it is not a selective 5-HT3 antagonist.

Q: Which of the following drugs does not stimulate 5-HT4 receptors?

Domperidone. ***Domperidone*** - Domperidone is a **dopamine D2 receptor antagonist** that acts as an antiemetic and prokinetic agent. - Unlike the other options, it primarily works by blocking D2 receptors in the **chemoreceptor trigger zone** and gastrointestinal tract, and does **not directly stimulate 5-HT4 receptors**. - Its prokinetic effects are achieved through **D2 receptor antagonism**, which increases gastrointestinal motility by removing dopaminergic inhibition of acetylcholine release. *Renzapride* - Renzapride is a **5-HT4 receptor agonist** and a 5-HT3 receptor antagonist, making it a powerful prokinetic agent. - Its prokinetic effects are directly mediated through the **stimulation of 5-HT4 receptors**, increasing gastrointestinal motility [1]. *Metoclopramide* - Metoclopramide is a **dopamine D2 receptor antagonist** with some **5-HT4 receptor agonist** activity [2]. - The 5-HT4 receptor agonism contributes to its prokinetic effects by enhancing acetylcholine release in the enteric nervous system [1]. *Cisapride* - Cisapride is a **selective 5-HT4 receptor agonist** that significantly increases gastrointestinal motility. - Its prokinetic action is almost entirely dependent on the **stimulation of 5-HT4 receptors**, leading to enhanced release of acetylcholine [1].

Q: All of the following drugs are commonly used in regimens against H. pylori, except:

Oxytetracycline. ***Oxytetracycline*** - **Oxytetracycline** is a tetracycline antibiotic, but it is **not a first-line drug** for *H. pylori* eradication and is less commonly used in standard regimens compared to other tetracyclines like doxycycline. - Its use in *H. pylori* eradication is limited due to **higher rates of resistance** and it is often considered only in **salvage therapies** if other regimens fail. *Amoxicillin* - **Amoxicillin** is a cornerstone **beta-lactam antibiotic** frequently included in **triple and quadruple therapy** regimens for *H. pylori* due to its efficacy and good safety profile. - It is active against *H. pylori* by **inhibiting cell wall synthesis**. *Bismuth Subcitrate* - **Bismuth subcitrate** is a key component of **bismuth quadruple therapy (BQT)**, which is recommended for *H. pylori* eradication, especially in areas with high clarithromycin resistance. - It has both **direct bactericidal effects** against *H. pylori* and helps **disrupt bacterial adhesion** to the gastric mucosa. *Omeprazole* - **Omeprazole** is a **proton pump inhibitor (PPI)** and is an essential component of nearly all *H. pylori* eradication regimens (triple, quadruple, concomitant). - PPIs **reduce gastric acid secretion**, which not only helps to heal peptic ulcers but also **enhances the stability and efficacy of antibiotics** against *H. pylori*.

Q: Granisetron is classified as a:

5HT3 antagonist. ***5HT3 antagonist*** - **Granisetron** is a highly selective **5-hydroxytryptamine type 3 (5HT3) receptor antagonist**. - It is primarily used to prevent and treat **chemotherapy-induced nausea and vomiting (CINV)** and **postoperative nausea and vomiting (PONV)**. *5HT2 antagonist* - While 5HT2 receptors are involved in various physiological processes, granisetron does not primarily act on these receptors. - Examples of **5HT2 antagonists** include agents like mirtazapine, which has antidepressant and antiemetic properties via other mechanisms. *Dopamine antagonist* - **Dopamine antagonists** (e.g., metoclopramide) primarily block dopamine D2 receptors and are also used as antiemetics. - Granisetron's primary mechanism of action is distinct from dopamine receptor blockade. *5HT3 receptor agonist* - An **agonist** would activate the 5HT3 receptor, which would likely *promote* nausea and vomiting, counteracting the intended therapeutic effect of granisetron. - Granisetron's antiemetic action is due to its ability to *block* these receptors.

Question 1

Proton pump inhibitors for peptic ulcer disease should be taken:

Accepted Answer

Before Breakfast

Answer

After Breakfast

Answer

Before Dinner

Answer

After Dinner

Question 2

Proton pump inhibitors are most effective when they are given:

Accepted Answer

Shortly before meals

Answer

After meals

Answer

Along with H2 blockers

Answer

During prolonged fasting periods

Question 3

Which one of the following is a 5-HT3 antagonist?

Accepted Answer

Ondansetron

Answer

Clozapine

Answer

Ergotamine

Answer

Orlistat

Question 4

Which of the following drugs does not stimulate 5-HT4 receptors?

Accepted Answer

Domperidone

Answer

Cisapride

Answer

Renzapride

Answer

Metoclopramide

Question 5

All of the following drugs are commonly used in regimens against H. pylori, except:

Accepted Answer

Oxytetracycline

Answer

Bismuth Subcitrate

Answer

Omeprazole

Answer

Amoxicillin

Question 6

Granisetron is classified as a:

Accepted Answer

5HT3 antagonist

Answer

Dopamine antagonist

Answer

5HT2 antagonist

Answer

5HT3 receptor agonist

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?